Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response

(2013) Leeyen Hsu et al.   Expert Review of Clinical Immunology

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial

(2012) In-Ho Song et al.   ANNALS OF THE RHEUMATIC DISEASES

Can we reduce the dosage of biologics in spondyloarthritis?

(2012) Ignazio Olivieri et al.   AUTOIMMUNITY REVIEWS

Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis

(2012) Suzanne Arends et al.   CURRENT OPINION IN RHEUMATOLOGY

Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria

(2012) K. M. Fagerli et al.   RHEUMATOLOGY

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

(2011) A Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease

(2011) Victoria Navarro-Compán et al.   CLINICAL RHEUMATOLOGY

High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)

(2011) F. Navarro-Sarabia et al.   RHEUMATOLOGY

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

(2010) P. Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis

(2010) Jaejoon Lee et al.   CLINICAL RHEUMATOLOGY

Dealing with immunogenicity of biologicals: assessment and clinical relevance

(2010) Gerrit J Wolbink et al.   CURRENT OPINION IN RHEUMATOLOGY

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

(2009) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES

ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis

(2008) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

(2008) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES